Product Information
NUVESSA VAGINAL 1.3% GEL is a brand product labeled by Exeltis USA, Inc., priced at $43.0273 per GM under NDC 00642746605. Its NADAC has been published 372 times since Aug 21, 2019.
FDA first approved this application on Mar 24, 2014.
The High Outlier badge above means this manufacturer's average price in the metronidazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
65 mg/5g
Manufacturer
Exeltis USA, Inc.NDC
00642746605
Classification
Brand
Dosage Form
GEL
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
METRONIDAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA205223FDA Approved
3/24/2014
On Market Since
3/10/2018
Pharmacological Classes
Price Statistics
The NADAC for NUVESSA VAGINAL 1.3% GEL has been published 372 times since Aug 21, 2019, and over the history we have for it it has risen 22.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $43.0273 per GM |
|---|---|
| All-time high | $43.0916 (May 13, 2026) |
| All-time low | $35.1575 (May 27, 2020) |
| 52-week high | $43.0916 |
| 52-week low | $41.0364 |
| Median price | $37.2009 |
| Average price | $37.7468 |
| Largest weekly change | +5.0% (Jan 10, 2024) |
| Weeks tracked | 372 |
| Tracking since | Aug 21, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the metronidazole market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Exeltis USA, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
metronidazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nitroimidazole Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NUVESSA VAGINAL 1.3% GEL?
The current National Average Drug Acquisition Cost (NADAC) for NUVESSA VAGINAL 1.3% GEL, manufactured by Exeltis USA, Inc., is $43.0273 per GM (NDC 00642746605), effective Sep 30, 2026.
How has the price of NUVESSA VAGINAL 1.3% GEL changed over time?
Over the history we have for it, the NADAC for NUVESSA VAGINAL 1.3% GEL has risen 22.4%. It has been tracked across 372 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for NUVESSA VAGINAL 1.3% GEL?
Since Aug 21, 2019, the NADAC for NUVESSA VAGINAL 1.3% GEL has ranged from a low of $35.1575 (May 27, 2020) to a high of $43.0916 (May 13, 2026), with a median of $37.2009 per GM.
Are there cheaper alternatives to NUVESSA VAGINAL 1.3% GEL?
No other NADAC-published product currently shares the active ingredient and strength of NUVESSA VAGINAL 1.3% GEL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NUVESSA VAGINAL 1.3% GEL?
NUVESSA VAGINAL 1.3% GEL (NDC 00642746605) is labeled by Exeltis USA, Inc., and CMS classifies it as a brand product.